Postoperative high-dose-rate brachytherapy alone in stage T1-3N0M0 oral cancer with negative prognostic factors: A retrospective study.

Luboš Tuček, Igor Sirák, Denisa Pohanková, Linda Kašaová, Jakub Grepl, Petr Paluska, Miroslav Hodek, Milan Vošmik, Banni Aml Mustafa, Eva Čermánková, Jiří Petera
{"title":"Postoperative high-dose-rate brachytherapy alone in stage T1-3N0M0 oral cancer with negative prognostic factors: A retrospective study.","authors":"Luboš Tuček, Igor Sirák, Denisa Pohanková, Linda Kašaová, Jakub Grepl, Petr Paluska, Miroslav Hodek, Milan Vošmik, Banni Aml Mustafa, Eva Čermánková, Jiří Petera","doi":"10.1016/j.brachy.2024.03.001","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate treatment outcomes and toxicity in patients with stage T1-3N0M0 oral cancer treated with surgery followed by high-dose-rate brachytherapy (HDR-BT).</p><p><strong>Methods and materials: </strong>Retrospective study of 50 patients with stage T1-T3N0 tongue and floor-of-mouth cancer who underwent tumour excision (+ elective neck dissection) followed by postoperative HDR-BT due to the presence of negative prognostic factors (close or positive resection margins, lymphovascular and/or perineural invasion, deep invasion). The plastic tube technique (dose: 18 x 3 Gy b.i.d.) was used. Survival outcomes, toxicity, and prognostic factors were evaluated.</p><p><strong>Results: </strong>At a median follow-up of 81 months (range, 4-121), actuarial 5-year local control (LC), nodal control (NC) and progression-free survival (PFS) rates were 79%, 69%, and 64%. After salvage treatment (surgery + external beam radiotherapy), LC, NC, and PFS increased to 87%, 77%, and 72.3%, respectively. Five-year overall survival and cancer-specific survival (CSS) rates were 73% and 77%. Treatmentrelated toxicity included two cases of mandibular osteoradionecrosis and five cases of small soft tissue necrosis. T stage was significantly correlated with nodal control (p=0.02) and CSS (p=0.04). Tumour grade correlated with DFS (p=0.01).</p><p><strong>Conclusion: </strong>Postoperative HDR-BT 18 x 3 Gy b.i.d. seems to be an effective method in patients with T1-3N0M0 oral cancer with negative prognostic factors after tumour resection.</p>","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brachytherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.brachy.2024.03.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To evaluate treatment outcomes and toxicity in patients with stage T1-3N0M0 oral cancer treated with surgery followed by high-dose-rate brachytherapy (HDR-BT).

Methods and materials: Retrospective study of 50 patients with stage T1-T3N0 tongue and floor-of-mouth cancer who underwent tumour excision (+ elective neck dissection) followed by postoperative HDR-BT due to the presence of negative prognostic factors (close or positive resection margins, lymphovascular and/or perineural invasion, deep invasion). The plastic tube technique (dose: 18 x 3 Gy b.i.d.) was used. Survival outcomes, toxicity, and prognostic factors were evaluated.

Results: At a median follow-up of 81 months (range, 4-121), actuarial 5-year local control (LC), nodal control (NC) and progression-free survival (PFS) rates were 79%, 69%, and 64%. After salvage treatment (surgery + external beam radiotherapy), LC, NC, and PFS increased to 87%, 77%, and 72.3%, respectively. Five-year overall survival and cancer-specific survival (CSS) rates were 73% and 77%. Treatmentrelated toxicity included two cases of mandibular osteoradionecrosis and five cases of small soft tissue necrosis. T stage was significantly correlated with nodal control (p=0.02) and CSS (p=0.04). Tumour grade correlated with DFS (p=0.01).

Conclusion: Postoperative HDR-BT 18 x 3 Gy b.i.d. seems to be an effective method in patients with T1-3N0M0 oral cancer with negative prognostic factors after tumour resection.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
有不良预后因素的T1-3N0M0期口腔癌术后单独高剂量近距离放疗:一项回顾性研究
目的:评价T1-3N0M0期口腔癌手术后高剂量率近距离放疗(HDR-BT)患者的治疗效果和毒性。方法和材料:回顾性研究50例T1-T3N0期舌口癌患者,由于存在不良预后因素(切缘闭合或阳性、淋巴血管和/或神经周围浸润、深部浸润),行肿瘤切除(+择期颈部清扫)并术后HDR-BT。采用塑料管技术(剂量:18 × 3gy b.i.d)。评估生存结果、毒性和预后因素。结果:中位随访81个月(范围4-121个月),精算5年局部控制率(LC)、淋巴结控制率(NC)和无进展生存率(PFS)分别为79%、69%和64%。经抢救治疗(手术 + 外束流放疗)后,LC、NC和PFS分别上升至87%、77%和72.3%。五年总生存率和癌症特异性生存率(CSS)分别为73%和77%。治疗相关毒性包括2例下颌骨放射性骨坏死和5例小软组织坏死。T分期与淋巴结控制(p=0.02)和CSS (p=0.04)显著相关。肿瘤分级与DFS相关(p=0.01)。结论:对于预后不良的T1-3N0M0口腔癌术后患者,术后HDR-BT 18 × 3gy b.i.d.可能是一种有效的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
From patient to pioneer: The inspiring journey of Dr. Brian Moran. Learning curve and proficiency assessment for gynecological brachytherapy amongst radiation oncology trainees in India: Results from a prospective study. A retrospective study on ruthenium-106 and strontium-90 eye-plaques treatment for retinoblastoma: 16-years clinical experience. The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer. Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1